Aditxt Inc

-0.01 (-2.48%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)12.01M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.5 Million
Adjusted EPS$0.23
See more estimates
10-Day MA$0.50
50-Day MA$0.93
200-Day MA$1.93
See more pivots

Aditxt Inc Stock, NASDAQ:ADTX

2569 Wyandotte Street, Suite 101, Mountain View, California 94043
United States of America
Phone: +1.909.488.0844
Number of Employees: 43


Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. It has a worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.